J&J Will Turn To Clinical Evidence To Overcome Reimbursement Challenges
This article was originally published in The Pink Sheet Daily
Reimbursement challenges in 2005 slowed adoption of Johnson & Johnson's injectable extended-release antipsychotic Risperdal Consta, the company reported Jan. 24
You may also be interested in...
Johnson & Johnson submitted an NDA Nov. 29 for its Risperdal follow-on paliperidone extended-release, the firm said Nov. 30
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.